STAT stories you may have missed 

Stephen Hahn, Trump’s new nominee for FDA commissioner, is battle-tested at putting out fires as a leader at major medical institutions.

Millennial caregivers face the same ups and downs as their older peers — but they take on the role at a point in their lives that can compound the challenges. 

The pivotal financial decisions that determine which biotechs will survive and which will fail are determined largely by social capital — not by science.

What Google technologies could end up in a Fitbit watch? STAT looks at that and other burning questions about Google’s big acquisition of the wearables company.

For the first time, the FDA has suggested drug makers recall some Zantac heartburn pills because some contain higher-than-normal amounts of NDMA. 

The FDA is this week considering new evidence and risks behind fecal matter transplants used as treatment for C. diff.  

Opinion: Some kids in pain need opioids. For doctors, that means walking a tightrope. 

Bill Gates spends billions on global health. With Alzheimer’s, his science adviser says, money is not the issue.